News Focus
News Focus
icon url

mick

04/22/20 10:01 AM

#2194 RE: TTIME #2192

i will read, thank you. 'Opgen (OPGN)'

icon url

mick

04/22/20 10:13 AM

#2195 RE: TTIME #2192

started off required filing; OpGen News - OPGN [confirmation of merger]
[selling shares to clear some debts]
http://ih.advfn.com/stock-market/NASDAQ/opgen-OPGN/stock-news/82280665/amended-statement-of-beneficial-ownership-sc-13d-a

Amended Statement of Beneficial Ownership (sc 13d/a)
April 22 2020 - 06:05AM
Edgar (US Regulatory) Print
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


SCHEDULE 13D

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

OpGen, Inc.
(Name of Issuer)

Common Stock $0.01 par value
(Title of Class of Securities)

68373L307
(CUSIP Number)

Oliver Schacht, Ph.D., Max-Eyth-Str.42
71088 Holzgerlingen, Germany
+49 (0)7031 49195-12
(Name, Address and Telephone Number of Persons Authorized to Receive Notices and Communications)

April 17, 2020
(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ?

*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page

The information required on this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1
NAMES OF REPORTING PERSONS


Curetis N.V. in Liquidation




2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
?

(b)
?


3
SEC USE ONLY







4
SOURCE OF FUNDS (SEE INSTRUCTIONS)


OO




5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)

?





6
CITIZENSHIP OR PLACE OF ORGANIZATION


Netherlands




NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
7
SOLE VOTING POWER


1,711,555*




8
SHARED VOTING POWER


0




9
SOLE DISPOSITIVE POWER


1,711,555*




10
SHARED DISPOSITIVE POWER


0




11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


1,711,555*




12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

?





13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)


11.65%**




14
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


CO





* See Item 5 of this statement on this Amendment to the Statement of Beneficial Ownership on Schedule 13D.
** Based on percentage as set forth in the Issuer’s Current Report on Form 8-K (No. 001-37367) filed with the Securities and Exchange Commission (the “SEC”) on April 2, 2020.

2
This Amendment No. 1 to the Statement of Beneficial Ownership on Schedule 13D (the “Amendment No. 1”) amends the Statement of Beneficial Ownership on Schedule 13D filed by Curetis N.V. in Liquidation on April 13, 2020 (the “Schedule 13D”). Except as amended and supplemented by this Amendment No.1, the Schedule 13D remains unchanged.

Item 3.
Source and Amount of Funds or Other Consideration.

Between April 17, 2020 and April 21, 2020, the Reporting Person sold 316,653 shares of Common Stock on the open market for a total of $758,217.75.

Item 4.
Purpose of the Transaction.

On April 1, 2020, the Issuer completed its business combination transaction with the Reporting Person pursuant to the implementation agreement dated as of September 4, 2019 (the “Implementation Agreement”), entered into by and among the Issuer, the Reporting Person and Crystal GmbH, a private limited liability company (Gesellschaft mit beschränkter Haftung) organized under the laws of the Federal Republic of Germany and a wholly owned subsidiary of the Issuer. In connection with the transaction, Mario Crovetto, Prabhavathi Fernandes, Ph.D., William E. Rhodes, III, and Oliver Schacht, Ph.D. were appointed to the board of directors of the Issuer (the “Board”). Pursuant to the terms of the Implementation Agreement, Oliver Schacht, Ph.D. and Johannes Bacher, who were formerly employed by the Reporting Person, were respectively appointed as Chief Executive Officer and Chief Operating Officer of the Issuer.

Pursuant to the Implementation Agreement, the Reporting Person received 2,028,208 shares of Common Stock in consideration of the sale and transfer of all of its shares in Curetis GmbH, a private limited liability company (Gesellschaft mit beschränkter Haftung) organized under the laws of the Federal Republic of Germany and certain other assets and liabilities of the Reporting Person.

On April 2, 2020, the Reporting Person registered with the Netherlands Chamber of Commerce for dissolution of the legal entity. The Common Stock held by the Reporting Person is expected to be transferred to the shareholders of the Reporting Person upon the dissolution of the Reporting Person, subject to the sale of a portion of such Common Stock as is necessary to satisfy remaining obligations and liabilities of the Reporting Person.

Between April 17, 2020 and April 21, 2020, the Reporting Person sold 316,653 shares of Common Stock on the open market for a total of $758,217.75 to satisfy remaining obligations and liabilities of the Reporting Person. Up to 88,987 additional shares of Common stock may be sold as is necessary to satisfy remaining obligations and liabilities of the Reporting Person.

Other than as described above, the Reporting Person does not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Person may change its purpose or formulate different plans or proposals with respect thereto at any time.

Item 5.
Interest in Securities of the Issuer.


(a)
– (b) As of April 21, 2020, the Reporting Person had sole voting and dispositive power over 1,711,555 shares of Common Stock, representing 11.65% of the outstanding Common Stock.


(c)
Except as otherwise disclosed in Item 3 and Item 4 of this Amendment No. 1, which is incorporated herein by reference, the Reporting Person has not effected any transactions in the Common Stock during the past sixty days. To the knowledge of the Reporting Person, none of the liquidators and members of the supervisory board of the Reporting Person listed in Annex A to the Schedule 13D effected any transactions in the Common Stock during the past sixty days.


(d)
Other than the Reporting Person, no person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Reporting Person’ securities.


(e)
Not Applicable.

Item 7.
Materials to be Filed as Exhibits.

Exhibit No.

Description

1
Implementation Agreement, dated as of September 4, 2019, by and among Curetis N.V., as Seller, and Crystal GmbH, as Purchaser and OpGen, Inc. (Incorporated herein by reference to Exhibit 2.1 of the Issuer’s Current Report on Form 8-K filed with the SEC on September 4, 2019)

3
SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: April 21, 2020


CURETIS N.V. IN LIQUIDATION


By:
/s/ Oliver Schacht

Name: Oliver Schacht

Title: Liquidator


By:
/s/ Johannes Bacher

Name: Johannes Bacher

Title: Liquidator


By:
/s/ Achim Plum

Name: Achim Plum

Title: Liquidator


4

icon url

mick

04/22/20 4:56 PM

#2197 RE: TTIME #2192

THANK YOU, AH READING; United States Coronavirus Cases:842,167,Deaths:47,123,Recovered:83,646

https://www.worldometers.info/coronavirus/country/us/
=====================================================

United States Coronavirus Cases:767,402,Deaths:41,229,Recovered:
71,396

https://www.worldometers.info/coronavirus/country/us/
========================================================================

United States Coronavirus Cases:761,484,Deaths:40,423,Recovered:
69,956

United States
Coronavirus Cases:
761,484


Deaths:
40,423


Recovered:
69,956

https://www.worldometers.info/coronavirus/country/us/

USA State Total Cases New Cases Total Deaths New Deaths Active,Cases
Source
https://www.worldometers.info/coronavirus/country/us/

United States
Coronavirus Cases:
356,414
302,919
---------------
..53,495

Deaths:
10,490
..8,243
---------------
..2,247


Recovered:
19,247
14,686
---------------
..4,561

icon url

mick

04/22/20 4:58 PM

#2198 RE: TTIME #2192

WOW 36% DIE ????? CLOSED CASES ,30,769 Cases which had an outcome:
83,646 (64%)
Recovered / Discharged

47,123 (36%)
Deaths

https://www.worldometers.info/coronavirus/country/us/
icon url

mick

04/24/20 1:18 PM

#2204 RE: TTIME #2192

is this still good ????? $OPGN everything intact PT $25.
1. Merger with Curetis/Ares on Approved on 3/10, pending OPGN approval
2.Ares Genetics to launch the rapid tests developed by BGI and approved in China on the European market in 2/2020

3.Curetis launch of FDA cleared Unyvero Panel for BAL available to U.S. customers since 1/20
4.Curetis/BCB agreement on bringing Unyvero to China pending their FDA, approval 1st qtr '20 $150m euro

5.OpGen working with FDA for Acuitas Isolates pending FDA 510k. Response to FDA anticipated in February $25m Potential
6.Patient accrual underway since 12/19, the Acuitas Urine for UTI, FDA De Novo clearance trial. 1st/2nd qtr $100m potential

7.Achievement of NY State Infectious Disease project. More states?
8.Acuitas Lighthouse revenue up 147%

9.FY2020 estimated revenue $15m doesn't include many catalyst
10.Ares R&D contract with undisclosed Leading Global IVD Corp to develop diagnostic solutions for infectious disease testing

11. Partners Qiagen Sandoz BGI Merck Thermo Fisher

icon url

mick

04/27/20 2:22 PM

#2212 RE: TTIME #2192

OpGen to Provide Business Update and Financial Results for the First Quarter 2020
April 27 2020 - 08:30AM
GlobeNewswire Inc. Print

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its first quarter 2020 financial results after the close of the U.S. financial markets on Thursday, May 7, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.
Conference Call Details
U.S. Dial-in Number: +1 (844) 420-8185
International Dial-in Number: +1 (216) 562-0481
Webcast: https://edge.media-server.com/mmc/p/iggnmjim
Conference ID: 8595009

Reply Details
U.S. Dial-in Number: +1 (855) 859-2056
International Dial-in Number: +1 (404) 537-3406
Conference ID: 8595009
Following the conclusion of the conference call, a replay will be available through May 14, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Joe Green
Edison Group
jgreen@edisongroup.com

icon url

mick

05/04/20 11:33 AM

#2220 RE: TTIME #2192

PPP LOAN;OPGN; Current Report Filing (8-k)
April 28 2020 - 04:47PM
Edgar (US Regulatory) Print
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K



CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934



April 22, 2020
Date of Report (Date of earliest event reported)

_________________



OpGen, Inc.
(Exact Name of Registrant as Specified in its Charter)

_________________

Delaware

(State or Other Jurisdiction of Incorporation)

001-37367

(Commission File Number)

06-1614015

(I.R.S. Employer Identification No.)



708 Quince Orchard Road, Suite 205
Gaithersburg, MD 20878
(Address of principal executive offices)(Zip code)

(240) 813-1260
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


? Written Communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock OPGN The Nasdaq Capital Market
Common Stock Warrants (IPO) OPGNW The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?






Item 1.01. Entry into a Material Definitive Agreement.

On April 22, 2020, OpGen, Inc. (the “Company”) entered into a Term Note (the “Company Note”) with Silicon Valley Bank (the “Bank”) pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. The Company’s wholly owned subsidiary, Curetis USA Inc. (“Curetis USA” and collectively with the Company, the “Borrowers”), also entered into a Term Note with the Bank (the “Subsidiary Note,” and collectively with the Company Note, the “Notes”). The Notes are dated April 22, 2020. The principal amount of the Company Note is $879,630, and the principal amount of the Subsidiary Note is $259,353.

In accordance with the requirements of the CARES Act, the Borrowers will use the proceeds from the Notes in accordance with the requirements of the PPP to cover certain qualified expenses, including payroll costs, rent and utility costs. Interest accrues on the Notes at the rate of 1.00% per annum. The Borrowers may apply for forgiveness of amount due under the Notes, in an amount equal to the sum of qualified expenses under the PPP, which include payroll costs, rent obligations, and covered utility payments incurred during the eight weeks following disbursement under the Notes. The Borrowers intend to use the entire proceeds under the Notes for such qualifying expenses.

Subject to any forgiveness under the PPP, the Notes mature two years following the date of issuance of the Notes and includes a period for the first six months during which time required payments of interest and principal are deferred. Beginning on the seventh month following the date of the Notes, the Borrowers are required to make 18 monthly payments of principal and interest. The Notes may be prepaid at any time prior to maturity with no prepayment penalties. The Notes provide for customary events of default, including, among others, those relating to breaches of their obligations under the Notes, including a failure to make payments, any bankruptcy or similar proceedings involving the Borrowers, and certain material effects on the Borrowers’ ability to repay the Notes. The Borrowers did not provide any collateral or guarantees for the Notes.

The foregoing description of the Notes is qualified by reference to the complete text of the Notes, copies of which are attached as Exhibit 10.1 and Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.


The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


Exhibit No. Document
10.1 Term Note between OpGen, Inc. and Silicon Valley Bank, dated April 22, 2020
10.2 Term Note between Curetis USA Inc. and Silicon Valley Bank, dated April 22, 2020









SIGNATURE



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





Date: April 28, 2020 OpGen, Inc.


By: /s/ Timothy C. Dec
Name: Timothy C. Dec
Title: Chief Financial Officer